Summary
28 / 100 · Bulios Score
What speaks for it
- Revenue grew by 58% a year over the last 3 years.
- Analysts expect revenue to grow by 25% this fiscal year.
What to watch
- The company made a loss over the last 12 months.
- The share price is above the Bulios Fair Price.
- It passes only 3 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 47% a year over 5 years. Over the last 3 years it grew by 58% a year. For the next fiscal year analysts expect revenue to grow by 25%.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $254.4M.
Profitability in detailIs it financially healthy?
Debt is a burdenOver the last 12 months it spent more cash than it brought in. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 9
- Hold 5
- Sell 0
Today's price within the analysts' price targets
The average target of $72.6 is 8.8% above today's price. 64% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Diagnostics 100%
By region
The company reports no revenue by region.
Diagnostics brings in 100% of revenue.
Segments in detail